User login
WASHINGTON — Fluoroquinolone resistance rose significantly over an 8-year period in hospitalized adults aged 65 and older with gram-negative bacterial infections, according to a report at the annual meeting of the American Geriatrics Society.
The safety and bioavailability of fluoroquinolones (FQs) have made them a popular choice for treating infections in older adults, wrote Jon P. Furuno, Ph.D., of the University of Maryland, Baltimore, and his colleagues in a poster presented at the meeting.
They collected microbiology data from all cultures that tested positive for gram-negative bacteria in patients aged 65 years and older admitted to the University of Maryland Medical Center between January 1998 and December 2005.
They analyzed 1,839 Escherichia coli, 554 Proteus mirabilis, 1,044 Pseudomonas aeruginosa, 1,068 Klebsiella, and 480 Enterobacter cloacae isolates.
FQ resistance increased significantly across all species, from 8.4% in 1998 to 26.9% in 2005. Species-specific significant increases in the percentage of resistant isolates were observed from 1998 to 2005 for E. coli (2.8% vs. 30.6%), P. mirabilis (7.4 % vs. 39.3%), and Klebsiella (1.7% vs. 9.3%). Resistance rates in P. aeruginosa and E. cloacae increased from 1998 to 2005, but the differences were not statistically significant.
The investigators recommended that prescribers consider the evidence of rising FQ resistance when choosing antibiotics for hospitalized older adults.
The study was funded by NIH, the CDC, and the Infectious Diseases Society of America. Dr. Furuno did not disclose any financial conflicts.
WASHINGTON — Fluoroquinolone resistance rose significantly over an 8-year period in hospitalized adults aged 65 and older with gram-negative bacterial infections, according to a report at the annual meeting of the American Geriatrics Society.
The safety and bioavailability of fluoroquinolones (FQs) have made them a popular choice for treating infections in older adults, wrote Jon P. Furuno, Ph.D., of the University of Maryland, Baltimore, and his colleagues in a poster presented at the meeting.
They collected microbiology data from all cultures that tested positive for gram-negative bacteria in patients aged 65 years and older admitted to the University of Maryland Medical Center between January 1998 and December 2005.
They analyzed 1,839 Escherichia coli, 554 Proteus mirabilis, 1,044 Pseudomonas aeruginosa, 1,068 Klebsiella, and 480 Enterobacter cloacae isolates.
FQ resistance increased significantly across all species, from 8.4% in 1998 to 26.9% in 2005. Species-specific significant increases in the percentage of resistant isolates were observed from 1998 to 2005 for E. coli (2.8% vs. 30.6%), P. mirabilis (7.4 % vs. 39.3%), and Klebsiella (1.7% vs. 9.3%). Resistance rates in P. aeruginosa and E. cloacae increased from 1998 to 2005, but the differences were not statistically significant.
The investigators recommended that prescribers consider the evidence of rising FQ resistance when choosing antibiotics for hospitalized older adults.
The study was funded by NIH, the CDC, and the Infectious Diseases Society of America. Dr. Furuno did not disclose any financial conflicts.
WASHINGTON — Fluoroquinolone resistance rose significantly over an 8-year period in hospitalized adults aged 65 and older with gram-negative bacterial infections, according to a report at the annual meeting of the American Geriatrics Society.
The safety and bioavailability of fluoroquinolones (FQs) have made them a popular choice for treating infections in older adults, wrote Jon P. Furuno, Ph.D., of the University of Maryland, Baltimore, and his colleagues in a poster presented at the meeting.
They collected microbiology data from all cultures that tested positive for gram-negative bacteria in patients aged 65 years and older admitted to the University of Maryland Medical Center between January 1998 and December 2005.
They analyzed 1,839 Escherichia coli, 554 Proteus mirabilis, 1,044 Pseudomonas aeruginosa, 1,068 Klebsiella, and 480 Enterobacter cloacae isolates.
FQ resistance increased significantly across all species, from 8.4% in 1998 to 26.9% in 2005. Species-specific significant increases in the percentage of resistant isolates were observed from 1998 to 2005 for E. coli (2.8% vs. 30.6%), P. mirabilis (7.4 % vs. 39.3%), and Klebsiella (1.7% vs. 9.3%). Resistance rates in P. aeruginosa and E. cloacae increased from 1998 to 2005, but the differences were not statistically significant.
The investigators recommended that prescribers consider the evidence of rising FQ resistance when choosing antibiotics for hospitalized older adults.
The study was funded by NIH, the CDC, and the Infectious Diseases Society of America. Dr. Furuno did not disclose any financial conflicts.